Condition: MPS IIIA · Sanfilippo Syndrome · Sanfilippo A · Sponsor: Ultragenyx Pharmaceutical Inc
The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.
This description comes directly from the study's public registry record.
Patients Contact: Trial Recruitment · 1-888-756-8657 · trialrecruitment@ultragenyx.com
HCPs Contact: Medical Information · 1-888-756-8657 · medinfo@ultragenyx.com
Always discuss trial participation with your own doctor first.
| Nationwide Children's Hospital | Columbus, Ohio, United States | Completed |
| Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Completed |
| Women's and Children's Hospital | North Adelaide, South Australia, Australia | Completed |
| Vall d'Hebron Barcelona Hospital Campus | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Clínico Universitario de Santiago | Santiago de Compostela, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02716246